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Sarcoidosis is a systemic granulomatous disease predominantly affecting the lungs. It
is believed to be caused by exposure to pathogenic antigens in genetically susceptible
individuals but the causative antigen has not been identiﬁed.The formation of non-caseating
granulomas at sites of ongoing inﬂammation is the key feature of the disease. Other aspects
of the pathogenesis are peripheral T-cell anergy and disease progression to ﬁbrosis. ManyT-
cell-associated cytokines have been implicated in the immunopathogenesis of sarcoidosis,
but it is becoming apparent that IL-12 cytokine family members including IL-12, IL-23, IL-
27, and IL-35 are also involved. Although the members of this unique cytokine family are
heterodimers of similar subunits, their biological functions are very diverse. Whilst IL-23
and IL-12 are pro-inﬂammatory regulators of Th1 andTh17 responses, IL-27 is bidirectional
for inﬂammation and the most recent family member IL-35 is inhibitory. This review will
discuss the current understanding of etiology and immunopathogenesis of sarcoidosis with
a speciﬁc focus on the bidirectional impact of IL-12 family cytokines on the pathogenesis
of sarcoidosis.
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INTRODUCTION
The term sarcoidosis was ﬁrst used in 1899 to describe patho-
logical features of skin lesions, but is currently used to describe
a systemic granulomatous inﬂammatory disease predominantly
affecting the lungs (Boeck, 1899; Müller-Quernheim et al., 2012).
The non-caseating granulomas observed in affected tissues remain
its key pathological feature (Heinle and Chang, 2014). More than
100 years of research have been unable to reveal the etiology and
pathogenesis of the disease.
Current investigations into the pathogenesis include studies
of gene polymorphisms and the role of possible infective and
non-infective antigens (Adrianto et al., 2012; Negi et al., 2012;
Dubaniewicz et al., 2013). Important questions that remain unex-
plained are how and why granulomas are formed and why
approximately 20% of all patients develop pulmonary ﬁbrosis
whereas themajority experience remission (Iannuzzi and Fontana,
2011; Müller-Quernheim et al., 2012; Broos et al., 2013; Loke et al.,
2013). Also yet to be explained is the observed anergy of peripheral
T-cells in affected patients (Lee et al., 2011).
The IL-12 family of cytokines, (IL-12, IL-23, IL-27, and
IL-35), have been implicated in other granulomatous inﬂam-
matory diseases such as tuberculosis and Crohn’s disease, and
a role for some of these cytokines has also been proposed in
sarcoidosis (Larousserie et al., 2004; Mroz et al., 2008; Judson
et al., 2012). Thus the purpose of this review is to discuss the
current understanding of the etiology and pathogenesis of sar-
coidosis with a focus on a possible role for the IL-12 family
cytokines.
EPIDEMIOLOGY
The incidence and prevalence of sarcoidosis varies between differ-
ent ethnic groups. Sarcoidosis is more common in females and
peak incidence is between 30–50 years (Rybicki and Iannuzzi,
2007). African Americans and Northern Europeans have the high-
est incidence rate ranging between 15–80/100.000 (Rybicki and
Iannuzzi, 2007). Interestingly more recent studies in different
countries all reveal an increased prevalence and incidence com-
pared to former reports, indicating that sarcoidosis might be
more common than previously thought (Deubelbeiss et al., 2010;
Nicholson et al., 2010; Erdal et al., 2012).
ETIOLOGY
Sarcoidosis is believed to be caused by exposure to antigens and
environmental agents in genetically susceptible individuals (Eishi,
2013).
The ACCESS study (A case control etiologic study of sarcoido-
sis) identiﬁed exposure to insecticides as well as mold, mildew,
and musty odors as risk factors pointing towards a role of micro-
bial bioaerosols in the pathogenesis of sarcoidosis (Newman et al.,
2004). The same study conﬁrmed a signiﬁcantly higher risk for ﬁrst
and second degree relatives of affected patients to be diagnosed
with sarcoidosis suggesting an involvement of genetic factors
(Rybicki et al., 2001).
POTENTIAL ANTIGENS
Several observations support the idea of microbial antigens play-
ing a role in the pathogenesis of sarcoidosis. Early studies found
that tissue samples from sarcoid patients injected into animals
caused granuloma formation (Iwai and Takahashi, 1976; Mitchell
et al., 1976). However when similar samples are disinfected they
do not cause granuloma formation, suggesting a cell-mediated
or microbial origin (Ikonomopoulos et al., 2000, 2006). Similarly
several case reports indicate that sarcoidosis might be transmit-
table via organ transplantations (Burke et al., 1990; Heyll et al.,
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1994; Padilla et al., 2002; Pukiat et al., 2011; Das et al., 2012).
Likewise, there are reports of both successful antibiotic and anti-
fungal treatment of sarcoidosis perhaps related to the potential
sarcoid antigens, Mycobacterium tuberculosis, Propionibacterium
acnes, and more recently, fungi (Tercˇelj et al., 2007, 2011a; Drake
et al., 2013; Takemori et al., 2014).
As sarcoidosis is a granulomatous disease, M. tuberculosis has
long been suspected to be involved, yet the bacterium has never
been isolated from sarcoid tissue (Milman et al., 2004). Nonethe-
less newer methods of detection have revealed that M. tuberculosis
antigens are present in sarcoid lesions (Gupta et al., 2007; Oswald-
Richter et al., 2012). Peripheral blood mononuclear cells (PBMCs)
as well as bronchoalveolar lavage ﬂuid (BAL) cells show hypersen-
sitivity when stimulated with those antigens, producing higher
amounts of interferon gamma (IFNy) than healthy controls with-
out Bacillus Calmette-Guerin vaccination (Oswald-Richter et al.,
2009, 2012; Ahmadzai et al., 2012).
Similarly, P. acnes antigens cause hypersensitivity in only a sub-
groupof patients but the bacterium is detected in and isolated from
sarcoid lymph nodes and tissue more frequently than in healthy
controls (Furusawa et al., 2012; Negi et al., 2012).
Fungal exposure is another risk factor for sarcoidosis andhigher
levels of beta-glucan (a fungal cell wall component) have been
found in BAL ﬂuid of patients compared to controls suggesting
a possible role for fungal antigens in sarcoidosis (Newman et al.,
2004; Tercˇelj et al., 2011b, 2013).
Despite the evidence for involvement of both M. tuberculosis
antigens and P. acnes as well as fungal exposure in the pathogenesis
of sarcoidosis, these organisms only amount for a subgroup of
patients leaving room for other theories that suggest a role for
non-microbial antigen such as autoantigens, serumamyloidA,and
human heat shock proteins (Salazar et al., 2000; Wahlstrom et al.,
2007, 2009; Chen et al., 2010; Bargagli et al., 2011; Dubaniewicz,
2013; Zhang et al., 2013).
GENE POLYMORPHISMS
Just as there is probably no single “sarcoid antigen,” there is no
single “sarcoidosis gene.” Multiple gene polymorphisms associ-
ated with sarcoidosis have been identiﬁed in different regional
subgroups but many of the results can not be reproduced in
different cohorts (Spagnolo and Grunewald, 2013). Human leu-
cocyte antigen (HLA) polymorphisms have received the most
attention with the hypothesis that sarcoidosis might be an anti-
gen driven disease. Whilst HLA-DRB1∗03 is associated with an
increased risk for Löfgren’s syndrome, HLA-DRB1∗07, ∗11, ∗14,
and ∗15 are related to chronic disease while HLA∗DRB∗01 and
∗13 seem to be protective (Grunewald et al., 2010; Sato et al.,
2010; Wijnen et al., 2010; Grubic et al., 2011; Zhou et al., 2011;
Wennerstrom et al., 2012). Only two non-HLA polymorphisms
have been conﬁrmed: annexin A11 being protective whereas a
butyrophilin-like 2 polymorphism is associated with chronic dis-
ease (Spagnolo et al., 2007; Milman et al., 2011;Wijnen et al., 2011;
Adrianto et al., 2012; Morais et al., 2012; Suzuki et al., 2012). More
recently, genome-wide association studies and single polymor-
phism analyses have also suggested a role for toll-like receptors,
the myeloid differentiation primary response gene (Judson et al.,
2012), IL-23 receptor (IL-23R), TNF-α, IL-10, NOTCH4, and
OS9 polymorphisms (Veltkamp et al., 2007; Vasakova et al., 2010;
Kim et al., 2011; Adrianto et al., 2012; Daniil et al., 2013; Hof-
mann et al., 2013; Song et al., 2014; Wijnen et al., 2014). As
yet, none of these ﬁndings have been shown to have external
validity and their potential clinical signiﬁcance and contribu-
tion to the pathogenesis remain to be determined. Thus the
literature shows the concept of sarcoidosis being an antigen-
driven immunoreaction in genetically susceptible individuals to
be accurate in principle but lacking in speciﬁcity in all patient
groups.
PATHOGENESIS
INITIATION, ACCUMULATION, AND EFFECTOR PHASE
Sarcoidosis is characterized bynon-caseating granulomas that typ-
ically consist of a core of Th1 cells and activated macrophages
surrounded by B-cells, ﬁbroblasts and CD8 lymphocytes as well
as Th17 cells, and Treg cells (Miyara et al., 2006; Iannuzzi and
Fontana, 2011; Ten Berge et al., 2012). Granuloma formation
can be explained in four stages: initiation, accumulation, effec-
tor phase, resolution/development of ﬁbrosis. It has traditionally
been explained by antigen-driven Th1 responses and interactions
between antigen presenting cells (APC) and Th1 cells but recent
advances have implicated Th17 in the process of granuloma for-
mation as well (Figure 1; Co et al., 2004; Chen and Moller, 2011;
Iannuzzi and Fontana, 2011; Müller-Quernheim et al., 2012; Broos
et al., 2013).
Th1 cell accumulation in the lungs is characteristic of sarcoido-
sis and these cells spontaneously produce increased amounts of
IL-2 and IFNγ in the BAL ﬂuid (Robinson et al., 1985; Mose-
ley et al., 1986; Prasse et al., 2000). The development of these Th1
cells depends on IL-12 and IL-18, both of which are elevated in the
BAL ﬂuid of sarcoidosis patients supporting a Th1-based hypoth-
esis of granuloma formation (Stoll et al., 1998; Yoshimoto et al.,
1998; Shigehara et al., 2001; Mroz et al., 2008).
Increased numbers of Th17 cells in BAL, blood and gran-
ulomatous tissue of sarcoidosis patients suggest a contribution
of these cells in the pathogenesis of sarcoidosis (Facco et al.,
2011; Ten Berge et al., 2012; Richmond et al., 2013). Th17 cells
are a subset of pro-inﬂammatory CD4+ cells that are associ-
ated with autoimmunity and antimicrobial defense (Bedoya et al.,
2013). They develop from naïve CD4+ T-cells in the presence
of TGFβ, IL-1β, IL-6, and IL-23 (Acosta-Rodriguez et al., 2007;
Wilson et al., 2007; Manel et al., 2008; Volpe et al., 2008). In
patients with sarcoidosis IL-1β, IL-6, and TGFβ are elevated in
the BAL ﬂuid compared to healthy controls and IL-23 has been
detected in granulomas creating a Th17 supportive microenvi-
ronment (Zissel et al., 1996; Idali et al., 2006; Judson et al., 2012;
Urbankowski et al., 2012). A few studies have analyzed the role of
the Th17 effector cytokines IL-17A/F, IL-21, and IL-22 in sarcoido-
sis, but the results are contradictory. One group demonstrated
that sarcoid Th17 cells produce more IL-17A compared to healthy
controls, whereas others demonstrated that IL-17 was down-
regulated after stimulation with P. acnes (Furusawa et al., 2012;
Richmond et al., 2013). In skin lesions of sarcoidosis patients,
IL-21 has been found to be elevated, whereas IL-17 and IL-
22 were not dysregulated (Judson et al., 2012). Thus there is
some evidence for a role of Th17 cells in granuloma formation
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FIGURE 1 | Granuloma formation –Th1/Th17 hypothesis. Initiation:
alveolar macrophages (AM) and dendritic cells (DC) are activated by a
putative antigen. DC migrates to lymph nodes and initiates Th1/Th17 cell
ampliﬁcation. Chemokines produced by alveolar macrophages attract Th1/17,
Treg, B-cells as well as CD8+ cells and ﬁbroblast and initiate granuloma
formation (effector phase). Both DC and macrophages produce cytokines
favoring Th1 and Th17 cells in sarcoidosis. Figure adopted from Broos et al.
(2013).
but more studies are needed to deﬁne the role of Th17 effector
cytokines.
RESOLUTION VERSUS FIBROSIS
The factors determining the clinical course of sarcoidosis, either
granuloma resolution or progression to ﬁbrosis, remain unclear
(Patterson et al., 2012). On a cellular level remission is believed to
occur through antigen clearance through a strong Th1 response
and recovery of regulatory T-cells (Treg; Müller-Quernheim et al.,
2012; Oswald-Richter et al., 2013). There is evidence support-
ing the theory that ﬁbrosis is caused by a switch from Th1
responses towards Th2 (Iannuzzi et al., 2007; Müller-Quernheim
et al., 2012). In line with this hypothesis, the concentration of the
Th2 cytokine IL-5 is lower in those without ﬁbrosis compared to
those with ﬁbrotic disease (Patterson et al., 2013). Further support
for a switch to Th2 responses is provided by several studies that
identiﬁed a Th2 driven immunosuppressive polarization of alveo-
lar macrophages (AM) in ﬁbrotic patients although these ﬁndings
remain controversial (Prasse et al., 2006;Wikén et al., 2010; Prokop
et al., 2011). Thus there is some evidence suggesting a contribu-
tion of Th2 responses to the development of ﬁbrosis but further
studies are required to conﬁrm this theory. It may also be worth
exploring a potential role of other immunosuppressive cytokines
such as IL-27 and IL-35.
IMMUNE PARADOX AND PERIPHERAL ANERGY
T-cell anergy is a term to describe hypo-responsiveness or
incomplete activation of T-cells after exposure to common
recall antigens, thought to be associated with a lack of
adequate co-stimulation or overexposure to co-inhibitory signals
(Crespo et al., 2013). In sarcoidosis, anergy is used to describe a
lack of reaction to skin antigen tests (delayed type hypersensitiv-
ity) and ex vivo exposure to common recall antigens in peripheral
blood (Mathew et al., 2008; Ahmadzai et al., 2012). This contrasts
with the extensive local inﬂammation at sites of active disease
and thus the phenomenon is also often referred to as an immune
paradox (Miyara et al., 2006). Mechanisms of the observed sar-
coid anergy are poorly understood and several theories have been
proposed including compartmentalization of immune competent
cells to the lung and, more recently, Treg, dendritic cells (DC),
and T effector (Teff) cell dysfunction (Miyara et al., 2006; Mathew
et al., 2008; Lee et al., 2011).
In fact it was initially hypothesized that the sarcoid peripheral
anergy could be due to increased numbers of Treg cells that sup-
press proliferationof Teff cells (Miyara et al., 2006). Further studies
conﬁrmed that Treg cells are ampliﬁed in blood, BAL, and lymph
node tissue of sarcoidosis patients, but these same studies indicate
that these cells may in fact be impaired in their repressor func-
tion and might even contribute to pro-inﬂammatory granuloma
formation (Taﬂin et al., 2009; Rappl et al., 2011; Oswald-Richter
et al., 2013). Interestingly, disease resolution is associated with
reversal of Th1 andTreg dysfunction (Oswald-Richter et al., 2013).
Thus the original idea of Tregs contributing to peripheral anergy
does not fully explain the phenomenon but nonetheless the cells
seem to be dysregulated in sarcoidosis. Interestingly, peripheral
blood and BAL sarcoid T-cells show selective hypersensitivity to
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possible sarcoid antigens while not only peripheral blood but also
sarcoid BAL cells are hypo-responsive to common recall antigens
(Ahmadzai et al., 2012; Oswald-Richter et al., 2013). It may be
that instead of peripheral anergy, sarcoidosis is rather character-
ized by selective hypersensitivity to disease related antigens and
hyporesponsiveness to common recall antigens. Further stud-
ies are required to compare the selective hypersensitivity and
anergy in cells from BAL and peripheral blood. Likewise a role for
immunosuppressive cytokines in the context of peripheral anergy
in sarcoidosis should also be considered.
IL-12 FAMILY CYTOKINES
Whilst the pathogenesis of granuloma formation in sarcoidosis
may be at odds with observed anergy in peripheral immune cells,
one possible unifying factor may be the IL-12 family of cytokines.
They are a unique group of heterodimeric cytokines composed
of one of the three alpha subunits p19, p35, or p28 and one of
the two beta subunits p40 or Epstein-Barr virus induced gene 3
(EBI3; Figure 2; Vignali and Kuchroo, 2012). p40 is the shared
beta-subunit of IL-12 and IL-23, whereas IL-27 and IL-35 con-
sist of the beta unit EBI3. The alpha subunit p19 is speciﬁc
for IL-23 as is p28 for IL-27, whereas p35 is shared by IL-12
and IL-35. Similarly they bind to heterodimeric receptors and
share ﬁve receptor subunits. Despite their common structures
the biological function of the members of this family is very
diverse (Figure 2). Whilst IL-12 and IL-23 are pro-inﬂammatory,
IL-27 is bi-directional in terms of being both pro- and
anti-inﬂammatory while IL-35 is strongly immunosuppressive
(Vignali and Kuchroo, 2012).
IL-12
A role for IL-12 in sarcoid granuloma formation is well estab-
lished (Figure 1; Iannuzzi and Fontana, 2011; Broos et al., 2013).
Multiple studies conﬁrm that IL-12p40 is elevated in blood, BAL,
and granulomatous tissue from sarcoidosis patients and PBMC as
well as BAL cells stimulated with sarcoid associated antigens pro-
duce higher amounts of IL-12 p40 in patients compared to healthy
controls (Table 1). The corresponding IL-12 receptor chain IL-
12Rβ1 is equally over-expressed in peripheral blood and BAL of
sarcoidosis patients (Rogge et al., 1999; Taha et al., 1999; Judson
et al., 2012). IL-12 is known to increase IFNγ production and
this holds true in sarcoid patients compared to controls (Shige-
hara et al., 2001). Recent studies suggest that Th17 cells may also
produce IFNγ in the presence of IL-12 (Annunziato et al., 2007;
Boniface et al., 2010). IFNγ has been shown to play a pivotal role
in lung granuloma formation in murine models of tuberculosis
(Cooper et al., 1997). It is thus likely that IL-12 (through pro-
moting IFNγ) is of similar importance in sarcoidosis granuloma
formation.
IL-23
IL-23 promotes the expansion and survival of Th17 cells,
which have recently been linked to sarcoid granuloma forma-
tion (Figure 1; Broos et al., 2013). Gene analyses have revealed
FIGURE 2 | IL-12 family members. IL-12 family members are
heterodimers sharing three α-chains (p35, p19, p28) and two β-chains
(p40, EBI3). Similarly the receptors also consist of heterodimers. Signaling
is mediated by the Jak-STAT family and affects different T-eff cell subsets.
IL-23 and IL-12 act mainly pro-inﬂammatory through the activation of Th17
and Th1 cells, IL-27 seems to act in a pro-inﬂammatory manner on naïve
T-cells and as an anti-inﬂammatory mediator on T-eff cells. IL-35 is
immunosuppressive, inducing iTr35 cells. Green arrows indicate
pro-inﬂammatory effects, red arrows represent anti-inﬂammatory
properties.
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Table 1 | Studies on IL-12 and IL-12 receptors in sarcoidosis.
Peripheral blood:
Method Result Reference
ELISA IL-12 p40 increased, IL-12p70 not detected (ELISA). Shigehara et al. (2003),
Hata et al. (2007)
Antibody detection IL-12Rβ2 not detected. Rogge et al. (1999)
mRNA, rtPCR IL-12Rβ1 is elevated compared to healthy controls, but IL-12Rβ2 is
not.
Judson et al. (2012)
Granuloma lesions:
Affected organ Method Result Reference
Skin mRNA, rtPCR IL-12p40, IL-12Rβ1 and IL-12Rβ2 are elevated compared to controls. Judson et al. (2012)
Myocardium IL12 ELISA and mRNA IL-12 is elevated (antibody not speciﬁed). IL-12p40 and IL-12p35
mRNA are present but only IL12p40 signiﬁcantly increased
compared to dilated cardiomyopathy controls.
Terasaki et al. (2008)
Lung Immunohistochemistry IL12p70 is overexpressed by epithelioid cells and macrophages as
well as giant cells.
Shigehara et al. (2001)
Lymph node mRNA, rtPCR IL-12p40 mRNA and IL-12Rβ2 mRNA is elevated, but not IL12p35 or
IL-12Rβ1
Hata et al. (2007)
Lung and lymph node Immunohistochemistry IL-12p40 is expressed by epithelioid cells and macrophages. Shigehara et al. (2003)
Lymph node mRNA IL-12p40 is signiﬁcantly increased compared to controls but not
IL-12p35.
Bergeron et al. (1997)
BAL:
Method of detection Result Reference
mRNA, ELISA IL-12p40 mRNA and protein levels are signiﬁcantly increased
compared to healthy controls. BAL macrophages express higher
levels of IL-12p70 both unstimulated and stimulated.
Moller et al. (1996)
ELISA IL-12p40 is elevated compared to healthy controls, but not IL-12p70. Shigehara et al. (2001),
Barbarin et al. (2003)
Cytometric bead array IL12p70 levels are signiﬁcantly higher in patients compared to
healthy controls.
Idali et al. (2006)
ELISA (not speciﬁed) IL-12 (not speciﬁed) is elevated compared to healthy controls. Kim et al. (2000), Meloni et al.
(2004), Antoniou et al. (2006),
Mroz et al. (2008)
FISH mRNA detection IL-12p40 signiﬁcantly elevated in patients with active sarcoidosis but
not inactive sarcoidosis.
Minshall et al. (1997)
mRNA IL-12Rβ1 and IL-12Rβ2 levels are elevated in sarcoidosis patients. Taha et al. (1999)
Antibody detection BAL cells of sarcoidosis patients express IL-12Rβ2. Rogge et al. (1999)
Stimulation assays with sarcoid antigens
Stimulus Cells Result Reference
P. acnes PBMC IL-12p40 mRNA levels are signiﬁcantly elevated in sarcoidosis
patients compared to healthy controls.
Furusawa et al. (2012)
β-glucan/LPS PBMC Spontaneous and post-stimulation IL-12 protein levels are higher in
patients compared to controls (IL 12 ELISA not further speciﬁed).
Rastogi et al. (2011)
NOD1/TLR4 ligands BALF IL12/23 p40 protein and mRNA levels are increased compared to
healthy controls.
Rastogi et al. (2011)
Multiple studies conﬁrm IL-12p40 and IL-12Rβ1 up-regulation in peripheral blood, BAL, and granulomatous tissue, while the corresponding IL-12p35 is not dysregulated
and IL-12p70 (the functional IL-12 protein) in most studies not detectable.
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Table 2 | Recent findings on pro- and anti-inflammatory effects of recombinant IL-27 on human cells in ex vivo studies.
Stimulated cells Finding Reference
Pro-inflammatory
Human monocytes Pro-inﬂammatory response in resting human monocytes.
TLR responses are enhanced in the presence of IL-27.
Kalliolias and Ivashkiv (2008)
Human APC Induction of pro-inﬂammatory CXCL10 and enhancement of TLR
responses.
Inhibition of LPS and CD40L mediated IL-10 production.




IFNγ andTNFα induction in bone marrow mononuclear cells. Li et al. (2011)
Anti-inflammatory
Human PBMC IL-27 upregulates IL-10 production in activated PMBCs. Fitzgerald et al. (2013)
Human PBMC Suppression of Th17 cell development and IL-17 production in the
presence of IL-23.
Fitzgerald et al. (2013)
Human DC IL-23 enhancement after stimulation with zymosan/IFNβ is
suppressed by IL-27.
Sweeney et al. (2011)
Murine studies on IL-27 suggest a bidirectional function of the cytokine in terms of pro- and anti-inﬂammatory immune modulation. Recent ex vivo studies on human
cells indicate that IL-27 might enhance inﬂammation in resting cells but inhibit immune responses in activated cells.
IL-23 receptor polymorphisms in sarcoidosis patients (Fischer
et al., 2011; Kim et al., 2011). Furthermore IL-23 receptormRNA is
elevated in the granulomatous skin lesions of sarcoidosis patients
and the same study also observed a trend for up-regulation of IL-
23 p19 in two thirds of sarcoid skin lesions, yet not in peripheral
blood (Judson et al., 2012). Upon ex vivo stimulation with toll-like
receptor 9 agonists, PBMCs of sarcoidosis patients produce less
IL-23 compared to healthy controls suggesting that IL-23 might
play a role in the formation of granulomas but not in peripheral
blood (Veltkamp et al., 2010). Given the fact that IL-23 mostly
acts as a pro-inﬂammatory cytokine through the promotion of
Th17 development, these ﬁndings underline a possible role of
Th17 cells in sarcoidosis. There is evidence that the Th17 cytokine
IL-17A is required in granuloma formation following infection
with mycobacteria (Fitzgerald et al., 2013). Since there are to date
no murine models of sarcoidosis it is difﬁcult to verify whether
Th17/IL-17A contribution is essential in sarcoidosis as well. Yet
IL-23 might promote IL-17A production by Th17 cells and thus
contribute to pulmonary granuloma formation.
IL-27
Somewhat uniquely, IL-27 has been shown to have both pro-
and anti-inﬂammatory effects (Table 2). Early studies focused on
pro-inﬂammatory effects as IL-27 was shown to initiate clonal
expansion of naïve T-cells and enhance INFγ production together
with IL-12 (Pﬂanz et al., 2002). It was also found to induce Th1
differentiation and showed pro-inﬂammatory effects on mono-
cytes (Owaki et al., 2005, 2006; Kalliolias and Ivashkiv, 2008).
In contrast to those ﬁndings, IL-27 receptor deﬁcient mice that
are infected with Toxoplasma gondii can still develop an immune
response but are then unable to down-regulate that response,
which ultimately proves to be fatal (Villarino et al., 2003). This
suggests a pivotal role of IL-27 in immune modulation and one
mechanism by which this is effected may be IL-10 induction in
Th1, Th2, Th17, and Treg cells. These effects seem to be mediated
via both the STAT1 and STAT3 proteins (Stumhofer et al., 2007).
IL-27 also promotes IL-10 – producing regulatory type 1 T-cells
(Treg1) and can directly suppress Th17 cells (Apetoh et al., 2010;
Sweeney et al., 2011; Fitzgerald et al., 2013). These results suggest
a bidirectional function of IL-27, and while it seems to induce a
pro-inﬂammatory response in naïve cells, the opposite is the case
in activated cells (Kalliolias and Ivashkiv, 2008; Fitzgerald et al.,
2013).
IL-27 and STAT3 were not dysregulated in sarcoid skin gran-
ulomas whereas STAT1 and STAT3 mRNA levels were elevated in
the peripheral blood of sarcoidosis patients compared to healthy
controls, but another group detected co-expression of the IL-27
subunits EBI3 and p28 (Figure 2) in epithelioid and multinucle-
ate granuloma cells in sarcoid lymph nodes, suggesting a role of
IL-27 in granuloma formation or resolution (Larousserie et al.,
2004; Judson et al., 2012). Interestingly IL-27R-/- mice produce
less IFNγ at sites of granuloma formation in tuberculosis mice
models suggesting that IL-27 might similarly contribute to early
stages of granuloma formation in sarcoidosis (Pearl et al., 2004). At
the same time IL-27 inhibits the production of TNF-α and IL-12 in
activated peritoneal macrophages, suggesting an IL-27-mediated
regulation of inﬂammation directed by macrophages in a murine
model of tuberculosis (Li et al., 2012). The cytokine has recently
been shown to be chemotactic for human DC and to impair HLA
Class I antigen presentation in those cells (Morandi et al., 2014)
and as the latter is believed to cause granuloma formation, IL-27
might thus also alter antigen presentation in sarcoidosis. IL-27
is a promising candidate for immune regulation in sarcoidosis
but further studies are required to conﬁrm IL-27 dysregulation
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in sarcoid tissue, analyse IL-27 expression in BALF and blood,
and determine the effects of the cytokine in sarcoidosis and clar-
ify whether it promotes inﬂammation and granuloma formation
or contributes to disease clearance through its anti-inﬂammatory
properties.
IL-35
IL-35 is themost recently identiﬁedmemberof the cytokine family.
It seems to bemainly expressed upon stimulation and there is some
evidence for human Treg cells as well as DC to be a source of this
cytokine (Seyerl et al., 2010; Li et al., 2012; Guttek and Reinhold,
2013). IL-35 is so far believed to be strictly immunosuppressive,
mediating regulatory B- and T-cell function and increasing IL-
35 – induced regulatory T-cells which express IL-35 (iTr35), as
well as inhibiting effector T-cell proliferation and Th17 develop-
ment and function (Niedbala et al., 2007; Collison et al., 2010,
2012; Olson et al., 2013; Ye et al., 2013; Wang et al., 2014). There
are only a few studies on the role of IL-35 in human diseases and
disease models to date and unlike the other IL-12 family members
there are currently no studies on IL-35 in sarcoidosis. In murine
models of airway inﬂammation, IL-35 suppressed airway hyper-
responsiveness via IL-17 suppression and is elevated in BAL upon
treatment with erythromycin suggesting a role for IL-35 in ame-
liorating airway inﬂammation (Bai et al., 2012; Whitehead et al.,
2012). Similarly transfer of iTr35 as well as Treg cells can cure
experimental inﬂammatory bowel disease in mice, but not if those
Treg cells lack either p35 or EBI3 (Collison et al., 2007, 2010). Sar-
coidosis often presents as airway inﬂammation and non-caseating
granulomas are a feature shared with Crohn’s disease, an inﬂam-
matory bowel disease. Since Treg cell dysfunction and Th17 cells
have also recently been linked to the pathogenesis of sarcoidosis
IL-35 is an interesting target for further research in sarcoidosis that
might contribute to disease clearance or the observed peripheral
anergy.
CONCLUSION AND PERSPECTIVES
The etiology and pathogenesis of sarcoidosis remain enigmatic.
Current concepts assume that the disease is caused by exposure
to disease related antigens in genetically susceptible individuals.
Although sarcoidosis was initially believed to be a Th1/IL-12/IFNγ
mediated disease, more recent advances have also revealed a
contribution of pro-inﬂammatory IL-23 and Th17 cells in granu-
loma formation. But little is known about IL-12 family members
and their possible role in ﬁbrosis development or peripheral
anergy. Whilst both IL-12 and IL-23 seem to be crucial pro-
inﬂammatory players in granuloma formation, the only ran-
domized controlled trial to date does not show efﬁcacy of IL-12
and IL-23 blockade with ustekinumab in sarcoidosis (Judson
et al., 2014). Given the fact that IL-12 enhances IFNγ which
then promotes granuloma formation the monoclonal IFNγ anti-
body fontolizumab is another promising drug in the treatment
of sarcoidosis showing some effects in phase 2 clinical trials in
Crohn’s disease (Hommes et al., 2006). The bidirectional IL-27
has also been detected in granulomas but further studies are
required in order to determine whether it enhances inﬂammation
or downregulates the excessive immune response at sites of
inﬂammation.
However, since both IL-35 and IL-27 also have immuno-
suppressive properties further studies on a potential con-
tribution to disease remission of these immunosuppressive
cytokines could shed more light on the pathogenesis of
sarcoid-related ﬁbrosis and anergy. A clearer immunosuppres-
sive function may indicate a role for stimulation of these
cytokine and their receptors in the treatment of sarcoidosis
and they could also be potential diagnostic markers for the
disease.
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